Girl here 💁🏼‍♀️ maybe to start we can lose the nasty derogatory sexist language.

Mark, is that you? I can’t imagine anyone else being so remarkably out of touch regarding RVNC.

Would love to see a show of hands. Who isn’t barely treading water or fully under on this stock? $6.66 won’t make most of us whole. I doubt any action from Teoxane will benefit retail investors.

Cosmetic MD, let’s not rewrite history. You were “lambasted” for blatant lies. This board has been collectively receptive to anecdotal injector experience. That is not what you contributed.

To the poster who said “I trusted,” I can’t find the post and I’m sorry you lost money. But perhaps you missed the significance of Dew’s username: do your own “dew” diligence. Investing is not as simple as finding a prophet and trusting them.

I am baffled at the choice to sell now, and at this price. If the BoD is upholding its fiduciary duty, I wonder what info is not public that supports this “merger”. I don’t have hope that litigation will benefit anyone, nor do I expect a knight in shining armor to gallop up waving a $10pps flag.

Like a bad breakup, I expect to spend many more nights wondering how this all went so wrong. I have only heard positive first hand accounts of the product. Wish everyone the best. It’ll be odd when this URL falls off my most visited Chrome shortcuts.

Sorry to hear that. It’s hard news to hear.

What is employee sentiment right now? Did senior management circulate the release to your team, or are you getting crickets?

Her reply to my follow up:

Oh, it’s really good. I haven’t even thought of it since it’s lasted longer than usual.


As succinct a rave as I could wish for.

I’ll throw a personal review in the mix, this is from my mother, late 60s, long time user of Botox and most recently Dysport. Her injector is a board certified MD in a major US city. She texted this before her appointment.

—

Dr K says it is faster acting than dysport and she’s used it on herself. She sees results in a day or so. She says her patients have tolerated it well and she likes the peptides since they promote collagen growth. She is all about using the best technology and she is brilliant.

—

She got it plus filler on face (not sure of specifics) and off label for migraines and on the neck for loose skin/vertical wrinkles. She was very happy with onset and results. This was back in November so I’ll have to circle back for her thoughts and share them too.

I don’t disagree with either of your replies, but they both sidestep the issue I raised of leadership’s recent, blatant lack of transparency and one may even go so far as to say dishonesty. It’s not “focusing on the past” to consider what was said 5 weeks ago, and pulling receipts on their recent flip flopping undermines any credibility to their 2025 EBITDA statements.

I am too invested in RVNC to hope for anything other than wild success so I can exit my position. But how can an investor make strategic long term decisions across their portfolio without reasonably transparent guidance. The best leadership can make mistakes and take time to right the ship, but the last several years have been too many sucker punches to not recognize a pattern and want out.

Any thoughts for those of us (most of us here, I believe) who invested pre-Dan Brown’s exit and are feeling increasingly like bag holders? Changes in leadership are always part of the gamble, but it’s hard not to come around to emmanow’s way of thinking given the recent behavior of MF and team.

Incredibly disappointed with this reply from IR.

Timeline:

Q4 earnings call:
Yes. Toby, do you want to hit that on a comfort level on the current debt structure?

Toby Schilke
“…when you take a look at what we've been trying to achieve over time and the operating leverage that we're generating on through 2023 decisions, we've taken to streamline our business with the reduction of Opel on and kind of moving towards a profitability that we feel is in sight with the guidance we've given…I feel like that really unlocks a lot of options on what's sort of our capital stack. Clearly, we'll always take prudent measures to finance the business and manage our maturities. But we feel like the first thing to do is prove out the business model continue the track record of success that we've had growing, diversify our HA with a cost structure that we've outlined here, and that will unlock continued operator opportunities on through either organic or sort of other financing alternatives.”

Then they announce the raise.

Foley comments about “noise in the marketplace” leading to interpretations of fulfilling covenants for 3rd tranche. Big middle finger to shareholders, buys a few meaningless shares himself.

Now we hear 3rd tranche is a no go. Unless terms were quietly renegotiated and draw date pushed out?

How can investors trust anything coming out of leadership?

Perhaps. But as I said it seems to be a well informed community and I doubt many of them would stay with a Dr unwilling to trail something that could bring such significant relief.

Why wouldn’t insurance companies push daxi, it costs less per treatment and J code has been issued. Even if it were an inferior treatment, payers are hardly lauded for pushing the more expensive or even effective option first.

Edit: bearish intel. Blame my toddler.

Does this charitable warning come from the kindness of your heart? Do you always spend your weekends doubling down warning bulls who are skeptical of your claims?

As up to speed as miss detox with her 100% solid source 😅

I welcome bearish intel and outlooks, but this board has been attracting a lot of vague pessimism lately.

CD boards are full of patients seeking quicker onset, longer duration, and less off time between payer approved injections. From what I’ve read they’re a generally well informed bunch of people in pain desperate for relief, actively engaged in conversation with their providers. If daxi works, word of mouth could drive uptake even if doctors stand in the way, as you claim.

Trying to parse out the successful business model to get daxi in faces —

Is this tiny sample those same doctors who rely on RNs and MAs to prep doses, but those skilled employees can’t figure out the simple math for Daxxify ratios (message 6222)? Also “ they need things simple for their staff that makes sure they spend their time productively,” if these drs are still charging the premium price for daxi, isn’t that well within their office’s interest to laminate a dosing how to sheet for their staff?

I believe you also mentioned high turnover, and that these high end doctor injectors spend their time tailoring tox’s to their patients, but not if it’s slightly more confusing for their registered nurse bartenders to shake up?

Is the daxi market then going to be in med spas where good enough injectors are willing to loudly offer promos to get people in the door, then trial and error different doses and injection patterns?

Apologies for the ramble, appreciate any additional color from those you speak to.

Rereading Toby’s remarks in Q&A through the lens of today’s news. Finding it increasingly difficult to trust mgmt. Would taking the final Athyrium tranche be bullish—MF has been praised here before for the structure of that debt. Cash on the books = more runway, but do we trust them to taxi and fly this plane? I don’t know.

Tim Lugo, William Blair.

This is John on for Tim. Thanks so much for taking our question. Just one from us. So I was just wondering if the team could provide commentary on the comfort level with the current debt structure.

Mark Foley

Yes. Toby, do you want to hit that on a comfort level on the current debt structure?

Toby Schilke

Yes, sorry about that. I didn't hear the question. Yes, I think when you take a look at what we've been trying to achieve over time and the operating leverage that we're generating on through 2023 decisions, we've taken to streamline our business with the reduction of Opel on and kind of moving towards a profitability that we feel is in sight with the guidance we've given both from a top line perspective and the OpEx perspective of having EBITDA positive in 2025.
I feel like that really unlocks a lot of options on what's sort of our capital stack. Clearly, we'll always take prudent measures to finance the business and manage our maturities. But we feel like the first thing to do is prove out the business model continue the track record of success that we've had growing, diversify our HA with a cost structure that we've outlined here, and that will unlock continued operator opportunities on through either organic or sort of other financing alternatives.

Good lord, do you scream aloud at the chemist when you compare regular and extra strength paracetamol bottles too?

This rant does very little to boost your reputation on this board.

I agree with Ed on this one. An anonymous anecdote from an EOLS rep, reported by someone who is long EOLS, about a product that threatens EOLS, isn’t a very helpful contribution to this board.

Wow, so if I listen to your stellar insight about this new tox that somehow fooled the FDA, I too can double my money?

You have no credibility on this site. You were caught in a lie, just own it and move on with your life. The fact that you’re a daily lurker and jump in so quickly to conversation makes it clear to me that you have a financial interest in seeing this company fail. That in itself is reason to ignore anything you say.

FWIW, I welcome criticism of the company and product. Nothing is perfect, no launch is perfect, and scrutiny is essential in the wise investor’s tool box. But you’ve made vague assertions about the clinical data that were called out as wrong with links, then you tried to hide your criticism behind the locked door of the board certified FB group.

The truth is coming out. Injectors are learning how to dose and place Daxxi, board certified derm's are posting glowing reviews. Customers are happy. Invest accordingly if you think it’s a dog, but don’t post here thinking you can salvage any credibility. I bet I speak for a lot of long time lurkers.